Navigation Links
BioDelivery Sciences Announces BEMA Buprenorphine Phase 3 Chronic Pain Study More Than 50% Recruited and on Schedule
Date:2/17/2011

RALEIGH, N.C., Feb. 17, 2011 /PRNewswire/ -- BioDelivery Sciences International, Inc. (Nasdaq: BDSI) announced today that enrollment of its Phase 3 trial assessing the efficacy and safety of BEMA Buprenorphine for the treatment of moderate to severe chronic pain is on schedule, with over half of the needed subjects enrolled.  

(Logo: http://photos.prnewswire.com/prnh/20110217/CL49801LOGO)

"We are very pleased with the enrollment to date for this pivotal Phase 3 study for our next product BEMA Buprenorphine," stated Dr. Andrew Finn, Executive Vice President of Product Development at BDSI.  "We are on schedule with enrollment as a result of a very focused effort both internally and with the enthusiastic support of an outstanding group of experienced investigators.  Based on current progress, we feel comfortable that we will meet our goal of reporting top-line results in the third quarter of this year.  Positive findings from this study would then allow for an anticipated NDA filing early in the second quarter of 2012."

BDSI believes that there remains a significant unmet medical need for potent new analgesics for the treatment of chronic pain.  Buprenorphine is an attractive option for development because of its potent analgesic properties, its differentiating characteristics from other opioids, and its DEA Schedule III designation, which means there is less addiction potential than Schedule II products.  According to Wolters Kluwer, opioid analgesic sales in the U.S. are in excess of $10 billion and growing, and BDSI believes that BEMA Buprenorphine has the potential to exceed $500 million in peak annual sales.

About BioDelivery Sciences International

BioDelivery Sciences International (Nasdaq: BDSI) is a specialty pharmaceutical company that is leveraging its novel and proprietary patented drug delivery technologies to develop and commercialize, either on its own or in partnerships with third parties, new applications of proven therapeutics.  BDSI is focusing on developing products to meet unmet patient needs in the areas of pain management and oncology supportive care.  BDSI's pain franchise currently consists of two products utilizing the patented BEMA technology.  ONSOLIS (fentanyl buccal soluble film) is approved in the U.S., Canada, and the E.U. (where it will be marketed as BREAKYL), for the management of breakthrough pain in opioid tolerant, adult patients with cancer.  The commercial rights are licensed to Meda for all territories worldwide except for Taiwan (licensed to TTY Biopharm) and South Korea (licensed to Kunwha Pharmaceutical Co.).  BDSI's second pain product, BEMA Buprenorphine, is being developed for the treatment of moderate to severe chronic pain and is in development in a high dose formulation for the treatment of opioid dependence.  Additional product candidates are being developed utilizing the BEMA technology for conditions such as nausea/vomiting (BEMA Granisetron) and migraine (BEMA "Triptan").  BDSI's headquarters is located in Raleigh, North Carolina.  For more information, visit www.bdsi.com.

BDSI® and BEMA® are registered trademarks of BioDelivery Sciences International, Inc.  ONSOLIS® is a registered trademark of Meda Pharmaceuticals, Inc.  BREAKYL is registered trademark of Meda Pharma GmbH & Co. KG.

Cautionary Note on Forward-Looking Statements

This press release and the statements of representatives and partners of BioDelivery Sciences International, Inc. (the "Company") related thereto contain, or may contain, among other things, certain "forward-looking statements" within the meaning of the Private Securities Litigation Reform Act of 1995. Such forward-looking statements involve significant risks and uncertainties. Such statements may include, without limitation, statements with respect to the Company's plans, objectives, projections, expectations and intentions and other statements identified by words such as "projects," "may," "could," "would," "should," "believes," "expects," "anticipates," "estimates," "intends," "plans," or similar expressions. These statements are based upon the current beliefs and expectations of the Company's management and are subject to significant risks and uncertainties, including those detailed in the Company's filings with the Securities and Exchange Commission.  Actual results (including, without limitation, the time for completion and results of the Phase 3 study of BEMA Buprenorphine) may differ significantly from those set forth in the forward-looking statements. These forward-looking statements involve certain risks and uncertainties that are subject to change based on various factors (many of which are beyond the Company's control).  The Company undertakes no obligation to publically update any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law.  Readers are cautioned that peak sales and market size estimates have been determined on the basis of market research and comparable product analysis, but no assurances can be given that such estimates are accurate or that such sales levels will be achieved, if at all.


'/>"/>
SOURCE BioDelivery Sciences International, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. MonoSol Rx, LLC Files Patent Infringement and False Marking Lawsuit Against BioDelivery Sciences International, Inc., MEDA Pharmaceuticals Inc., and Aveva Drug Delivery Systems, Inc.
2. Sanofi-aventis and Sunnybrook Health Sciences Centre Agree to Develop Treatment for Diabetic Foot Ulcers
3. Medical Devices and Diagnostics Analyst Joins MLV to Further Expand its Coverage of the Life Sciences Sector
4. OXIS International to Present at the Lippert/Heilshorn Life Sciences and Medtech Virtual Conference on February 17
5. Caliper Life Sciences Fourth Quarter and Fiscal Year 2010 Financial Results Conference Call Notice
6. 3-V Biosciences Promotes Stephen R. Brady to Chief Business Officer
7. Caliper Life Sciences IVIS® Optical Imaging System Adoption Surpasses 1000 Units: Validated Drug Research, Discovery and Development Tool Enables Advances in Personalized Medicine
8. Sangamo BioSciences Announces Presentation at the 13th Annual BIO CEO & Investor Conference
9. Neurocrine Biosciences Announces Conference Call and Webcast to Present Fourth Quarter and Year-End 2010 Financial Results
10. Caliper Life Sciences Announces Availability of Automated TruSeq™ Next Generation Sequencing Protocols
11. DARA BioSciences to Present Live at RetailInvestorConferences.com on February 3
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/27/2016)... April 27, 2016 Tie-up with ... initiative to save newborns   Fortis ... & newborns in collaboration with Breast Milk Foundation (BMF), a ... Pasteurized Human Milk Bank, ,Amaara, in Delhi-NCR today. This non-profit ... source for infants and should be available to babies deprived ...
(Date:4/27/2016)... , April 27, 2016 Shire plc ... Jeff Poulton , Chief Financial Officer, will present at the ... Boston, MA on Wednesday, May 04, 2016, 10:00 ... will be available on the Presentations and Webcasts section of ... of the webcast will be available on this same website ...
(Date:4/27/2016)... , April 27, 2016 ... ), a developer of a new generation of ... positive overall survival results for Paclical/Apealea in the ... 789 patients with epithelial ovarian cancer. These preliminary ... Paclical/Apealea in combination with carboplatin versus Taxol in ...
Breaking Medicine Technology:
(Date:4/30/2016)... ... April 30, 2016 , ... Dr. Trevor Gardner, ... EMED, today signed a multifaceted agreement which will allow for the research and ... Department of Natural and Applied Sciences, Allied Health and Nursing will work together ...
(Date:4/30/2016)... ... , ... Orlando-based Maximized Living has selected Dr. Nick Wilson of Indianapolis to ... the care of Maximized Living doctors at the London Olympics in 2012, U.S. wrestlers ... sending the largest contingent of elite chiropractors to Rio to support and care for ...
(Date:4/29/2016)... ... ... In an article published April 16th on the New York ... injections, which she underwent in order to feel more at home at this year’s ... article explains that Ms. Mirmelli’s situation is not unique; many plastic surgeons say they’ve ...
(Date:4/29/2016)... ... 2016 , ... Shamangelic Healing, Sedona Arizona's Premier Center ... BRAIN and New Mood Daily-Stress Formula for brain optimization and wellness to their ... store is just one more way Shamangelic Healing supports people’s quest for health, ...
(Date:4/29/2016)... ... April 29, 2016 , ... The American workforce ... stability, even security. Most importantly, employees are the single most important asset in ... workers so unhappy? , Just under half of American workers are emotionally checked ...
Breaking Medicine News(10 mins):